Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.07 USD
Change Today -0.0234 / -25.05%
Volume 3.1K
As of 8:10 PM 10/2/15 All times are local (Market data is delayed by at least 15 minutes).

ligand pharmaceuticals-ge rt (LGNYZ) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/30/15 - $0.09
52 Week Low
04/7/15 - $0.03
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

ligand pharmaceuticals-ge rt (LGNYZ) Related Businessweek News

View More BusinessWeek News

ligand pharmaceuticals-ge rt (LGNYZ) Details

Ligand Pharmaceuticals Incorporated operates as a biotechnology company in the United States. The company’s commercial programs include Promacta, an oral medicine that increases the number of platelets in the blood; Kyprolis that is used for the treatment of multiple myeloma; bazedoxifene, which is used for the treatment of postmenopausal osteoporosis; and Captisol-enabled Noxafil-IV, a formulation of posaconazole for intravenous (IV) use. Its late-stage development programs include Captisol-enabled Melphalan IV, MK-8931 Beta-Secretase Inhibitor, Captisol-enabled SAGE-547, Sparsentan, Captisol-enabled Delafloxacin-IV, Captisol-enabled Carbamazepine-IV, IRAK4 Inhibitor Program, LTP Technology with Omega-3 Fatty Acids, Biologic Therapeutics Platform, Captisol-enabled Topiramate IV, Lasofoxifene, and Captisol-enabled Lamotrigine IV. The company’s internal product development programs include Glucagon Receptor Antagonist Program, Oral Human Granulocyte Colony Stimulating Factor Program, LTP Platform, Kinase Inhibitors, HepDirect HCV Inhibitor Program, and other programs. Its therapies in development portfolio addresses the unmet medical needs of patients for a range of diseases, including hepatitis, multiple myeloma, muscle wasting, Alzheimer’s disease, dyslipidemia, diabetes, anemia, epilepsy, focal segmental glomerulosclerosis, and osteoporosis. Ligand Pharmaceuticals Incorporated has alliances with GlaxoSmithKline, Amgen, Inc., Merck, Pfizer, Baxter International, and Eli Lilly and Co. The company was founded in 1987 and is headquartered in La Jolla, California.

19 Employees
Last Reported Date: 02/23/15
Founded in 1987

ligand pharmaceuticals-ge rt (LGNYZ) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $510.2K
President and Chief Operating Officer
Total Annual Compensation: $375.4K
Vice President, General Counsel and Secretary
Total Annual Compensation: $288.9K
Compensation as of Fiscal Year 2014.

ligand pharmaceuticals-ge rt (LGNYZ) Key Developments

Ligand Pharmaceuticals Incorporated Expands Global License and Supply Agreements with Sage Therapeutics

Ligand Pharmaceuticals Incorporated announced that it has expanded its global license and supply agreements with SAGE Therapeutics (SAGE) to now also cover the use of Captisol in the development and commercialization of SAGE-689. Under the terms of the license, Ligand received a licensing fee and will be eligible to receive potential milestone payments, tiered royalties on future net sales and revenue from Captisol material sales. SAGE will be responsible for all costs related to the program.

Ligand Pharmaceuticals and its Subsidiary Enter into Sublicense Agreement with Retrophin

On September 17, 2015, Ligand Pharmaceuticals Incorporated and its wholly owned subsidiary entered into Amendment No. 4 to Sublicense Agreement with Retrophin Inc. to amend certain terms of the Sublicense Agreement, dated February 16, 2012, the Sublicense Agreement. Under the Sublicense Agreement, Ligand granted to Retrophin an exclusive worldwide sublicense, with further sublicense rights, to intellectual property rights related to Sparsentan and related compounds. Sparsentan is an investigational therapeutic agent which acts as both a potent angiotensin receptor blocker as well as a selective endothelin receptor antagonist preferential for receptor type A. Retrophin is paying Ligand $1.0 million as consideration to enter into Amendment No. 4, partly in exchange for rights related to potential expansion in the Asia Pacific region. Ligand has also amended or updated certain other non-financial terms of the Sublicense Agreement. Under the amended Sublicense Agreement, the 9% net royalty obligations on worldwide sales due to Ligand is unchanged and potential milestones payments are materially unchanged.

Ligand Pharmaceuticals Incorporated Amends and Restates the Bylaws

Effective September 9, 2015, the board of directors of Ligand Pharmaceuticals Incorporated amended and restated the bylaws of the company in order add a forum selection clause in a new Section 7 under Article IX specifying Delaware as the sole and exclusive forum for derivative or breach of duty suits or proceedings, claims arising under the General Corporation Law of Delaware, the Certificate of Incorporation or Bylaws of the company, or suits pertaining to the internal affairs of the company.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
LGNYZ:US $0.07 USD -0.0234

LGNYZ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $41.38 USD +0.62
Allergan plc $288.00 USD +5.65
Johnson & Johnson $93.93 USD +0.76
Pfizer Inc $33.08 USD +1.24
Valeant Pharmaceuticals International Inc C$239.62 CAD +1.33
View Industry Companies

Industry Analysis


Industry Average

Valuation LGNYZ Industry Range
Price/Earnings 57.6x
Price/Sales 24.9x
Price/Book 25.7x
Price/Cash Flow 54.4x
TEV/Sales 19.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact LIGAND PHARMACEUTICALS-GE RT, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at